JP2007525465A5 - - Google Patents

Download PDF

Info

Publication number
JP2007525465A5
JP2007525465A5 JP2006514911A JP2006514911A JP2007525465A5 JP 2007525465 A5 JP2007525465 A5 JP 2007525465A5 JP 2006514911 A JP2006514911 A JP 2006514911A JP 2006514911 A JP2006514911 A JP 2006514911A JP 2007525465 A5 JP2007525465 A5 JP 2007525465A5
Authority
JP
Japan
Prior art keywords
antibodies
htnf
fragments
bind
regions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006514911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007525465A (ja
Filing date
Publication date
Priority claimed from US10/441,059 external-priority patent/US7892563B2/en
Application filed filed Critical
Publication of JP2007525465A publication Critical patent/JP2007525465A/ja
Publication of JP2007525465A5 publication Critical patent/JP2007525465A5/ja
Pending legal-status Critical Current

Links

JP2006514911A 2003-05-20 2004-05-20 重症急性呼吸症候群(sars)の治療のための、組成物および方法 Pending JP2007525465A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/441,059 US7892563B2 (en) 2003-05-20 2003-05-20 Methods for treatment of severe acute respiratory syndrome (SARS)
PCT/US2004/015864 WO2005018535A2 (en) 2003-05-20 2004-05-20 Compositions and methods for treatment of severe acute respiratory syndrome (sars)

Publications (2)

Publication Number Publication Date
JP2007525465A JP2007525465A (ja) 2007-09-06
JP2007525465A5 true JP2007525465A5 (https=) 2008-01-24

Family

ID=33449934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006514911A Pending JP2007525465A (ja) 2003-05-20 2004-05-20 重症急性呼吸症候群(sars)の治療のための、組成物および方法

Country Status (14)

Country Link
US (2) US7892563B2 (https=)
EP (1) EP1624850A4 (https=)
JP (1) JP2007525465A (https=)
KR (1) KR20060023968A (https=)
CN (1) CN1976720A (https=)
AU (1) AU2004266111B8 (https=)
BR (1) BRPI0410467A (https=)
CA (1) CA2526431A1 (https=)
IL (1) IL171972A0 (https=)
MX (1) MXPA05012497A (https=)
NO (1) NO20056073L (https=)
NZ (1) NZ543655A (https=)
RU (1) RU2411042C2 (https=)
WO (1) WO2005018535A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
JP4845091B2 (ja) * 2005-08-09 2011-12-28 学校法人日本大学 コロナウィルスの遺伝子を切断するリボザイム
CA2651775A1 (en) * 2006-05-08 2008-05-08 University Of Virginia Patent Foundation Compositions and methods for treating anthrax lethality
AU2007272970C1 (en) * 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ, インコーポレイテッド Fc融合タンパク質の血清半減期を増加させるための組成物および方法
KR101935072B1 (ko) * 2011-05-19 2019-01-03 모찌다 세이야쿠 가부시끼가이샤 오줌 검체를 사용한 호흡기 감염증의 진단
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
CN111228480A (zh) * 2020-02-24 2020-06-05 浙江正熙生物医药有限公司 抗人TNF-α抗体在制备用于治疗病毒感染的药物中的应用
BR112022017986A2 (pt) 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticorpos anticoronavírus e métodos de uso
CA3174634A1 (en) * 2020-03-11 2021-09-16 Biolinerx Ltd. Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
WO2021186439A1 (en) * 2020-03-16 2021-09-23 Bar-Ilan University Molecules that target proteins of coronaviruses and uses thereof as anti-viral "cocktail"
CN113425722B (zh) * 2020-03-23 2025-06-24 上海市浦东新区公利医院(第二军医大学附属公利医院) 苦味受体激动剂及其在预防和治疗SARS-CoV-2相关传染病中的应用
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
US11648236B2 (en) * 2020-04-03 2023-05-16 Veru Inc. Methods of treating coronavirus
EP4132526A1 (en) * 2020-04-08 2023-02-15 Nostrum Pharmaceuticals, LLC Compositions and methods for the prophylaxis and/or treatment of viral infections or conditions associated therewith
TW202204375A (zh) * 2020-04-15 2022-02-01 美商寇峇有限公司 治療冠狀病毒感染之方法
IL274327A (en) * 2020-04-28 2021-10-31 Zaltzman Pinchas Antiviral preparations
EP3906922A1 (en) * 2020-05-07 2021-11-10 4Living Biotech New compositions and methods of treating covid-19 disease
WO2021226437A1 (en) * 2020-05-07 2021-11-11 Bio-Rad Laboratories, Inc. Sars-cov-2 immunoassay and materials therefor
MX2022014083A (es) * 2020-05-15 2023-02-22 Altered Labs Llc Kit de tratamiento de suplemento de refuerzo inmunologico y metodos de uso.
EP4182687A4 (en) * 2020-07-20 2024-09-11 Bio-Rad Laboratories, Inc. IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR
EP3957364A1 (en) * 2020-08-20 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases
US20220273641A1 (en) * 2020-10-07 2022-09-01 Vera Mikhailov Method for treating coronavirus infections including SARS-CoV-2
WO2022264097A1 (en) * 2021-06-17 2022-12-22 Lupin Limited Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
IL310012A (en) 2021-07-14 2024-03-01 Regeneron Pharma Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4720489A (en) 1984-10-15 1988-01-19 Douglas Shander Hair growth modification with ornithine decarboxylase inhibitors
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3650150T2 (de) 1985-08-16 1995-04-27 The Rockefeller University, New York, N.Y. Modulator der anabolischen Aktivität und seine Verwendungen.
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5196430A (en) 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5096906A (en) 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
EP0288088B1 (en) 1987-04-24 1994-03-09 Teijin Limited Detection of tumor necrosis factor; monoclonal antibody and kit
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
DE3817955A1 (de) 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
ES2072330T5 (es) 1989-05-18 2013-06-24 Yeda Research And Development Co., Ltd. Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
DE69027121T3 (de) 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
CA2032191C (en) 1989-12-13 1999-05-18 David Wallach Expression of the recombinant tumor necrosis factor binding protein i (tbp-i)
DE4027616A1 (de) 1990-08-31 1992-03-05 Boehringer Mannheim Gmbh Verfahren zur bestimmung von polymerase-aktivitaet
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
ATE190629T1 (de) 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
WO1993001211A1 (en) 1991-07-05 1993-01-21 Peptide Technology Limited Peptide which abrogates tnf and/or lps toxicity
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5547979A (en) 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5594106A (en) 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
DE69502378T2 (de) 1994-01-20 1998-10-01 British Biotech Pharm Metalloproteinaseinhibitoren
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
AU698393B2 (en) 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6107273A (en) 1995-01-24 2000-08-22 Thomas Jefferson University Tumor necrosis factor inhibitors
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
US5824519A (en) 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
GB9607120D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
EP0912519A1 (en) 1996-05-20 1999-05-06 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
AU4988697A (en) 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
US5833994A (en) 1997-01-08 1998-11-10 Paracelsian, Inc. Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
US6140368A (en) 1997-05-05 2000-10-31 The Regents Of The University Of California Naphthols useful in antiviral methods
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US5883131A (en) 1997-07-09 1999-03-16 Pfizer Inc. Cyclic sulfone derivatives
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
WO1999015524A1 (en) 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
DE19813802A1 (de) 1998-03-27 1999-11-11 Retro Tech Gmbh Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
US6251868B1 (en) 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
MXPA00012842A (es) 1998-06-24 2004-06-22 Univ Emory Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
WO2000009150A2 (en) 1998-08-17 2000-02-24 Prendergast Patrick T Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
US6080580A (en) 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6114517A (en) 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
SG101418A1 (en) * 1999-03-30 2004-01-30 Showa Denko Kk Production process for magnetic recording medium
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6632667B1 (en) * 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
US7056695B2 (en) * 2000-03-02 2006-06-06 Xencor TNF-α variants
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies

Similar Documents

Publication Publication Date Title
JP2007525465A5 (https=)
DK1322960T4 (da) Allergen-mikroarrayassay
JP2007535490A5 (https=)
EA200800812A1 (ru) Композиции антитела против cd3
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
NO20073655L (no) Antistoffer mot IL-13 reseptor alfa 1 og anvendelser derav
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
EP2295465A3 (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
JP2007527865A5 (https=)
IL222756A0 (en) Antibodies and antigen-binding fragments thereof that bind to a sclerostin polypeptide, compositions containing the same and methods for the production thereof
WO2010009987A3 (en) Diagnostic antibody assay
JP2010515717A5 (https=)
ZA200702879B (en) Single domain antibodies against TNFR1 and methods of use therefor
WO2006086208A3 (en) 5-fluoro-uracil immunoassay
IL191617A (en) An antibody linked to polyubiquitin, a method for its preparation, a pharmaceutical preparation containing it and its uses
WO2005026209A3 (en) Monoclonal antibodies against hmgb1
WO2003078600A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
WO2006102200A3 (en) Docetaxel immunoassay
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
WO2005030806A3 (en) Norovirus monoclonal antibodies and peptides
EP2332988A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2006015098A3 (en) Taxol immunoassay
NO20051715L (no) HCV assay
DE602006016736D1 (de) Für lipopolysaccharide (lps) des pseudomonas aeruginosa-iats-o11-serotyps spezifische humane monoklonale antikörper